Vivus, Auxilium sign Canadian marketing deal

|About: Vivus, Inc. (VVUS)|By:, SA News Editor

Vivus (VVUS) has licensed the exclusive rights to market its Stendra erectile-dysfunction drug in the U.S. and Canada to Auxilium Pharmaceuticals (AUXL).

Under the agreement, Vivus will receive as much as $300M in regulatory and sales milestones, including $30M upfront and $15M contingent upon a potential label amendment. Vivus will also receive royalties on any sales.

Auxilium expects to launch Stendra by the end of 2013.

Vivus shares +1.8% premarket. (PR)

This was corrected on 10/14/2013 at 03:45 PM. The item originally suggested the marketing deal was only in Canada.